Charles O Noble
ZoneOne Pharma, USA
Biography
Charles Noble completed his PhD in chemistry at Louisiana State University working with conductive polymers and dendrimers. His postdoctoral work at University of California San Francisco focused on antibody-targeted immunoliposomes and drug delivery to brain tumors. As a Senior Scientist at Merrimack Pharmaceuticals (formerly Hermes Biosciences) he was a key contributor to development of a liposomal irinotecan (MM-398) which was approved by the FDA in 2015 for treating pancreatic cancer and is marketed as Onivyde®. In 2011 he co-founded ZoneOne Pharma, Inc. to develop treatments for transfusional iron overload and has the role of President and Scientist. He has co-authored over 40 publications.